Conditions: Non-Squamous Non-Small Cell Lung Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 62
Healthy volunteers: no

Brief summary:
This open-label, non-randomized, one-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as single-agent first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer who show epidermal growth factor receptor (EGFR) activating mutations. Patients will receive Tarceva 150 mg orally daily until disease progression or unacceptable toxicity occurs.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: erlotinib [Tarceva]
Intervention descriptions: intervention 1: 150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason

Protocol document: